A preclinical study in Science Translational Medicine reports that folate receptor alpha (FOLR1) helps colorectal tumors resist immune checkpoint therapy. Researchers found FOLR1 correlated with poorer outcomes and mechanistically dampened STAT1/MHC-1 signaling, limiting CD8+ T-cell recognition. Blocking FOLR1 with the approved antibody-drug conjugate mirvetuximab soravtansine restored anti-tumor immunity and resensitized tumors to anti–PD-1 in mouse models. The data position FOLR1 as a potential predictive biomarker and combination target for patients who do not respond to checkpoint blockade.